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Background: Medication non-adherence is prevalent. We assessed the effect of electronic prescribing (e-prescribing)
with formulary decision support on preferred formulary tier usage, copayment, and concomitant adherence.
Methods: We retrospectively analyzed 14,682 initial pharmaceutical claims for angiotensin receptor blocker and
inhaled steroid medications among 14,410 patients of 2189 primary care physicians (PCPs) who were offered
e-prescribing with formulary decision support, including 297 PCPs who adopted it. Formulary decision support
was initially non-interruptive, such that formulary tier symbols were displayed adjacent to medication names.
Subsequently, interruptive formulary decision support alerts also interrupted e-prescribing when preferred-tier
alternatives were available. A difference in differences design was used to compare the pre-post differences in
medication tier for each new prescription attributed to non-adopters, low user (<30% usage rate), and high user
PCPs (>30% usage rate). Second, we modeled the effect of formulary tier on prescription copayment. Last, we
modeled the effect of copayment on adherence (proportion of days covered) to each new medication.
Results: Compared with non-adopters, high users of e-prescribing were more likely to prescribe preferred-tier
medications (vs. non-preferred tier) when both non-interruptive and interruptive formulary decision support were
in place (OR 1.9 [95% CI 1.0-3.4], p = 0.04), but no more likely to prescribe preferred-tier when only non-
interruptive formulary decision support was in place (p = 0.90). Preferred-tier claims had only slightly lower mean
monthly copayments than non-preferred tier claims (angiotensin receptor blocker: $10.60 versus $11.81, inhaled
steroid: $14.86 versus $16.42, p < 0.0001). Medication possession ratio was 8% lower for each $1.00 increase in
monthly copayment to the one quarter power (p < 0.0001). However, we detected no significant direct association
between formulary decision support usage and adherence.
Conclusion: Interruptive formulary decision support shifted prescribing toward preferred tiers, but these medications
were only minimally less expensive in the studied patient population. In this context, formulary decision support did
not significantly increase adherence. To impact cost-related non-adherence, formulary decision support will likely need
to be paired with complementary drug benefit design. Formulary decision support should be studied further, with
particular attention to its effect on adherence in the setting of different benefit designs.
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Adherence to medications is a critical component of
controlling chronic illness. Nonetheless, multiple investi-
gators have documented adherence rates of approxi-
mately 60% [1], with little to no improvement over time
[2]. Furthermore, meta-analysis shows this poor adherence
to be associated with increased mortality [3]. Furthermore,
the cost of adherence-related hospital admissions alone
has been estimated at $100 billion annually in the US [4].
Our analysis focuses on the potential of electronic pre-
scribing (e-prescribing) with formulary decision support
(FDS) to help physicians know, and thus choose, the
lowest-tiered medication within a given class. This choice
could minimize patients’ copayments and thereby improve
medication adherence.
Prior research has shown that FDS is associated with in-
creased usage of generic and other lower-tiered medica-
tions [5-8]. Furthermore, lower copayments are known to
be associated with improved adherence [9,10]. Evidence of
these two relationships suggests that implementing e-
prescribing with FDS could improve adherence. However,
a 2014 issue brief found no direct study of this topic [11].
We sought to evaluate whether FDS could reduce patient
medication costs, and thereby improve adherence.
Methods
Ethics statement
The RAND Corporation Institutional Review Board ap-
proved this analysis. The requirement for informed con-
sent was waived because this was a retrospective analysis
of existing health care data in which the researchers did
not have access to identifiable patient information that
would have allowed patients to be contacted.
Study design
This was a retrospective difference in differences analysis
of de-identified records from e-prescribing adopter and
non-adopter cohorts before and after FDS implementation.
Setting
In late 2004, Horizon Blue Cross Blue Shield of New
Jersey (BCBSNJ) led an initiative to offer subsidized
iScribe standalone electronic prescribing (e-prescribing)
software to high volume prescribers. In a prior publica-
tion, we described levels of e-prescribing use among 297
primary care physicians (PCPs) who participated in this
initiative by adopting iScribe during 2005 [12]. They
were compared with 1892 PCPs who were also offered
the e-prescribing system during this time period, but did
not adopt it. We found that solo practitioners, pediatri-
cians, and physicians with more patients from predom-
inantly African American zip codes were less likely to
adopt e-prescribing. In the current study, we compare the
pharmaceutical claims (claims) of these PCPs’ assignedprimary care patients before and after implementation
of FDS.
Isolating and classifying pharmaceutical claims
We obtained a dataset containing all claims for medica-
tions dispensed between June 3, 2003 and July 21, 2006
and submitted to Horizon BCBSNJ for the assigned pri-
mary care patients of the 2189 PCPs. Because there are
other ways of increasing brand to generic switches (e.g.
state laws that require generic medications be dispensed
when available), we selected two medication classes
without generic medications available during the time
period considered. We thus isolated all claims for angio-
tensin receptor blocker (ARB) and inhaled steroid (IS)
medications (Figure 1). For the latter class, we recognize
that adherence calculated from claims is often lower
than for pills. Nonetheless, prior studies show that pro-
portion of days covered (PDC) can be reliably measured
within this lower range [13-16].
Then, we excluded claims with less than 15 days sup-
plied to eliminate trial starts and a small number of
claims that appeared erroneous. We further restricted
the dataset to first, new claims (‘index’ claims) because
the decision to select a given medication within a class
is considered most when a medication is started. This
restriction was accomplished by excluding any claims
preceded by another same-class (ARB or IS) claim dur-
ing the prior six months. Finally, for our adherence ana-
lysis, we also excluded index claims from 2006. Since all
of the patients were continuously enrolled through June
30, 2006, this ensured that we had six further months of
claims to calculate adherence subsequent to each index
claim.
Different pharmaceutical benefit plans, and their effect
on patient copayments
Among studied patients, pharmaceutical benefit plan
coverage was heterogeneous. The most common benefit
plan used a three tiered formulary with ascending copay-
ments for generic, preferred, and non-preferred brand
medications. However, some patients had two tiered
plans with identical copayments for all branded medica-
tions. Others had percentage coinsurance requirements
that did not differ by brand status. A small proportion of
patients were required to pay all costs at the pharmacy
and later submit for reimbursement, in which case
copayments could not be deduced from claims. Finally,
even among patients with similar plan structures, there
were differences in terms of actual copayment amounts,
coinsurance percentages, deductibles, out-of-pocket max-
imums, flex spend plans, and “gap” insurance that would
affect patients’ actual out-of-pocket costs. As with nearly
every study using pharmaceutical claims as a data source,
we did not have access to all of this cost information, but
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Figure 1 Pharmaceutical claim exclusion process.
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claims to model the overall relationship between copay-
ment and tier. For example, if a patient’s plan required
10% coinsurance for a $200 claim, the patient responsibil-
ity on the claim would show as $20, so we would use $20
as the ‘copayment’ for that claim.
Intervention – initial non-interruptive FDS changed to
combined non-interruptive and interruptive FDS
For the aforementioned e-prescribing initiative, Caremark
began activating participating physicians’ e-prescribing
software in January of 2005, and continued to do so on a
rolling basis throughout 2005. We isolated the claims ofFigure 2 Passive formulary decision support indicates medication tierpatients attributed to the 297 PCPs studied in our prior
manuscript, each of whom activated their iScribe e-
prescribing software during calendar year 2005. For
each study PCP, Caremark provided us with an e-
prescribing activation date.
During the study period, the software initially used only
non-interruptive FDS, but later added interruptive FDS.
Thus, e-prescribers were initially only exposed to non-
interruptive FDS, which consisted of automatic display of
the medication tier at the time of e-prescribing (Figure 2).
Beginning September 16, 2005, the software exposed
e-prescribers to both non-interruptive and interruptive FDS,
which included the following: For the ARB medication.
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tan, olmesartan, or telmisartan were advised to “Consider
preferred brands Avapro, Diovan”. Atacand was added on
February 17, 2006 after it also became a preferred brand.
For the IS medication class, physicians prescribing inhaled
beclomethasone, flunisolide, or triamcinolone were ad-
vised to “Consider preferred brands Flovent HFA, Pulmi-
cort Turbuhaler”. Thus, for the purposes of our analysis,
each study claim was linked to the appropriate PCP
e-prescribing adoption date and subsequently classified as
belonging to one of these three time periods: Pre-FDS,
e-prescribing with non-interruptive FDS only, and e-
prescribing with (both) interruptive and non-interruptive
FDS.
Because there was no date of e-prescribing activation
for non-participating PCPs, we assigned each non-
participating PCP a ‘synthetic’ activationdate by random
sampling with replacement from study PCPs’ actual ac-
tivation dates. This assignment was done to make the
distribution of activationdates similar in both groups,
such that our analyses would be robust to secular
trends. We then used these dates to separate control
PCPs’ claims into pre and post-FDS claims. Because
interruptive FDS was added on a specific date, we used
this date to further classify post-FDS claims into the
period of non-interruptive FDS only versus the period
of both interruptive and non-interruptive FDS.
We could not definitively determine whether individ-
ual claims had been electronically prescribed, but we
were able to associate each claim with a PCP’s level of e-
prescribing usage. Because of our prior finding that
levels of e-prescribing usage varied greatly but were
generally stable, we classified e-prescribing users as high
versus low users based on whether they used it more or
less than 30% of the time. Based on our previous ana-
lysis of usage levels, this represented the 70th percentile,
and the mean usage rate among this subgroup was 61%
(61 e-prescriptions per 100 claims) [12].Outcome variables – medication tier, patient copayment,
and adherence
Medication tier was found in Horizon BCBSNJ formularies.
Claims contained patient copayment data. Because cost var-
iables often contain a skewed distribution with many outly-
ing data points [17,18], a Box-Cox transformation was used
to determine the best way of transforming the patient
copayment variable to minimize root mean square error.
Adherence was quantified using the proportion of days
covered (PDC): after a patient filled a new medication, the
PDC was the percentage of the subsequent 180 days when
any medication within the index class (ARB or IS) was
available to them, based on the days of medication supplied
according to claims data [19].Covariates and intervention variables
Caremark provided physician specialty and practice size
information. Horizon BCBSNJ provided de-identified
demographics for each of the PCPs’ assigned primary care
patients. As described in prior work, we used patients’ zip
codes to estimate their household income, race (black vs
white) and ethnicity (Hispanic vs non-Hispanic) [12]. Dos-
ing frequency was calculated from claims data.
Data analysis
We first compared characteristics of the three groups of
studied PCPs and their patients, including across the
three time periods studied. We made bivariate compari-
sons between FDS use and medication tier, between tier
and patient copayments, between patient copayments
and adherence, and finally directly between FDS use
and adherence. We then constructed four multiple re-
gression models to control for possible confounders.
Because our prior work found that usage of the FDS
intervention varied widely [12], the FDS:tier model includes
the interaction between the extent of FDS usage and
the type of FDS present. We used claims from non-
participating PCPs in corresponding times periods (before
e-prescribing activation, after activation of e-prescribing
with non-interruptive FDS, and after the addition of inter-
ruptive FDS) to control for secular trends. A difference in
differences approach was used to compare the temporal
differences within like PCPs across groups of PCPs. The es-
timated effects in this model were obtained from general-
ized estimating equations (GEEs) with a logit link function.
The tier:copayment model used multiple linear regres-
sion, and assumed that insurers only consider tier and
medication class in determining copayments. These co-
variates were therefore the only ones tested. Linear
mixed effects models were used to examine copayment:
adherence and FDS:adherence associations. In the copay-
ment:adherence and FDS: adherence regression models, a
one-dimensional random effect was used to control for
clustering of patients within PCPs.
Because these three underlying models required irrecon-
cilable specification differences, the final model that directly
analyzed the relationship between FDS and adherence was
not just an identical, overarching model, but rather a separ-
ate analysis. The regression models were generally con-
structed by beginning with all available and theoretically
tenable predictor variables included, and then using a back-
ward variable selection procedure to eliminate covariates
determined not to be associated. A p-value threshold of
0.05 and model fit criteria were jointly used to make this
determination. Model fit was assessed using the quasi-
likelihood information criterion for the FDS:Tier model
and the Akaike's information criterion for the copayment:
adherence model. All analyses were performed using SAS,
release 9.2 (SAS Institute, Inc; Cary, NC).
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tier and tier:copayment model estimates to project the ef-
fect of FDS on patient copayments. We also used the tier:
copayment and copayment:adherence model estimates to
project the effect of tier on adherence, and we combined
all three model estimates to project the effect of FDS on
adherence. Finally, because the FDS:tier model was the
most important new knowledge generated in our analyses,
and because there is extensive prior evidence regarding
tier:copayment and copayment:adherence relationships,
we combined our FDS:tier model estimates with this prior
evidence. Specifically, we used annual survey results from
the Kaiser Family Foundation that included copayments
for different medication tiers to summarize existing
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*Fisher’s exact test was used for categorical comparisons because of low or zero co
**Patients having an index ARB or IS claim.landmark meta-analysis of cost-sharing studies to under-
stand copayment:adherence relationships [20,21]. In doing
so, we generated FDS:copayment and FDS:adherence illus-
trative projections that were independent of the tier:
copayment and copayment:adherence relationships we
found in the studied setting. Adherence projections as-
sumed a baseline PDC of 60%.
Results
Table 1 summarizes differences between PCPs, patients,
and claims included in the analyses. A similar comparison
across the three studied time periods found them to be
generally similar, except that more patients of pediatrician
PCPs had index claims in the latter two time periods. Our
prior publication included 2189 PCPs [12], but only 1831utical claims included in the analysis
Non-users Low users High users p-value*
1570 (86%) 187 (10%) 74 (4%)
490 (31%) 67 (36%) 28 (38%) 0.03
838 (54%) 103 (55%) 35 (47%)
2 (0.13%) 1 (0.53%) 1 (1.4%)
235 (15%) 16 (8.6%) 10 (14%)
783 (50%) 64 (34%) 29 (39%) <0.01
612 (39%) 90 (48%) 39 (53%)
148 (10%) 30 (16%) 6 (8.1%)
20 (1.3%) 3 (1.6%) 0 (0%)
2 (0.13%) 0 (0%) 0 (0%)
12327 (86%) 1505 (10%) 578 (4.0%)
45.8 ± 19.5 49.2 ± 16.0 47.7 ± 18.3 <0.0001
6367 (52%) 776 (52%) 285 (49%) 0.55
2132 (18%) 261 (18%) 92 (17%) 0.13
6970 (58%) 878 (60%) 310 (56%)
2899 (24%) 321 (22%) 152 (27%)
12563 (86%) 1533 (10%) 586 (4.0%)
9094 (72%) 1238 (81%) 448 (77%)
1563 (12%) 125 (8.2%) 65 (11%)
(Synthetic)
August 4, 2005 July 27, 2005 August 19, 2005 0.60
June 2, 2005 June 2, 2005 June 8, 2005
September 29, 2005 September 27, 2005 October 12, 2005
unts in some cells. ANOVA was used for continuous variables.
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sion here. Figure 1 shows how many claims were excluded
in each of the steps described above. The bivariate com-
parison of FDS use and tier shows that high user PCPs ex-
posed to interruptive and non-interruptive FDS selected
preferred brands more often than low and non-users, and
more often than high users with only non-interruptive
FDS (Table 2). Within any one group of PCPs, the largest
measured change in preferred tier prescribing occurred
with the addition of interruptive FDS among high user
PCPs, as their preferred tier prescribing increased to 78%.
This represents a significant increase from the prior 61%
preferred tier prescribing among these PCPs when using
non-interruptive FDS only. In that time period, this
group’s rate of 61% was not different from other PCPs. Be-
cause we found a significant secular trend of increasing
preferred brand usage across the three time periods, even
among the non-user PCPs, we continued to use synthetic
adoption dates in the regression analyses to account for
this secular trend.
Before developing a model, we graphed the unadjusted
proportion of claims for the preferred medication tier in
each of three user groups over time (Figure 3). This
figure shows that the groups were statistically similar
in the pre-FDS period and remained so when non-
interrruptive FDS was added, but that the high user
group had a higher proportion of preferred tier claims
after interruptive FDS was added. This increase appeared
to moderate in the final measurement period. When we
constructed two separate figures for ARB and IS claims,
the patterns over time were similar, but IS claims were
more likely to be preferred tier.
The multiple regression results in Table 3 demonstrate
that patients whose PCPs were high users in a time
period with both types of FDS were more likely to have
preferred tier claims, and this association persisted even
after adjusting for medication class (OR 1.9, p = 0.04).
Because medication class itself had an unexpectedly
strong effect in our model, we also constructed separate
models for each class and found the odds ratios to be
similar (ARB OR 2.0, p = 0.02; IS OR 1.6, p = 0.27). The








Non user PCPs 63% 69%
Low user PCPs (<30%) 59% 60%
High user PCPs (>30%) 57% 61%
All PCPs 62% 67%
p-value <0.01 0.19
*p-values are for comparisons within user groups across time and within each timethe lower number of claims in this model, which only
represented 27% of the claims in the joint model. We
used parameters from the joint model to estimate that
the net effect of interruptive alerts were 15% and 8% in-
creases in the probability of preferred tier prescribing for
ARB and IS, respectively.
A Box-Cox transformation found that the monthly
copayment variable was best represented in the tier:
copayment and copayment:adherence regressions as the
monthly copayment to the one fourth power. This trans-
formation made the regressions more robust to outlying
data points that commonly cause a right-skewed distri-
bution of cost data. Compared to non-preferred brands,
preferred brand ARB and IS medications had estimated
median monthly copayments of $10.60 and $14.86, ver-
sus $11.81 ($1.21 higher) and $16.42 ($1.56 higher) for
non-preferred brands, respectively (p < 0.0001). Given
the aforementioned odds ratio of 1.9 and its associated
15% and 8% expected increases in the probability of
using preferred tier medications, high users of e-
prescribing with both interruptive and non-interruptive
FDS would be expected to decrease patients’ median
copayments for ARB and IS medications by $0.18 and
$0.12 per month on average, compared to non-users of
FDS (for ARB, $0.18 = $11.81 – [15% × $10.60 + (100% –
15%) × $11.81]) ).
When we substituted the tier:copayment relationship
present in our dataset with national survey data from
2013 [21], we projected that the studied FDS would have
reduce expected medication copayments by $3.49 (based
on increasing the likelihood of receiving a preferred
brand prescription with a $29 copayment by 15%, and
decreasing the likelihood of receiving a non-preferred
brand prescription with a $52 copayment by 15%). This
is much greater than the expected lower monthly copay-
ments of $0.12 - $0.18 associated with FDS calculated
from our observed tier:copayment relationship.
Bivariate comparisons of adherence showed that lower
copayments were associated with higher adherence rates.
Multiple regression demonstrated that these associations
were still present even after adjustments were made for
medication class, dosing frequency, and patient incomeof three user groups in each of three time periods







period across user groups.
Figure 3 Unadjusted percent preferred medication tier in each of three user groups over time*.
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not substantially alter the estimates or p values in this
model.
We projected that the aforementioned copayment dif-
ferences of $1.21 and $1.56 associated with the use of a
preferred brand medication would be expected to raise
PDC by 0.40 percent (ARB: 74.62% to 75.02%, IS:
73.34% to 73.74%). However, the aforementioned lower
copayment of $0.18 associated with high use ofTable 3 Logistic regression evaluating the relationship betwe
tier (n = 14660)*
PCP or Claim characteristic†
Medication class – inhaled steroid
E-prescribing with formulary decision support (FDS) usage
Low users (<30% of time)
High users (>30% of time)
Time periods
Non-interruptive FDS time period
Interruptive and Non-interruptive FDS time period
Interactions
Low users during time period with Non-interruptive FDS only
Low users during time period with Interruptive and Non-interruptive FDS
High users during time period with Non-interruptive FDS only
High users during time period with Interruptive and Non-interruptive FDS‡
*Variables without association, and therefore not used as predictors in this model, a
pharmaceutical claims per month, and patient race and income (as estimated from
†The referent categories were as follows: angiotensin receptor blocker medication c
e-prescribing activation.
‡As noted in the text, this odds ratio remained in the range of 1.6-2.0 in five other
physician specialty, (3) controlled for practice size, (4) restricted to ARB only, and (5e-prescribing ARB with both interruptive and non-inter-
ruptive FDS would only be expected to increase PDC by
0.06 percent. (Using $11.18 as an initial expected ARB
copayment, −0.08 * [(11.00)0.25 – (11.18)0.25] = 0.06%). Al-
though we projected this estimate by linking three under-
lying regression estimates, there was not a statistically
significant direct association between high FDS usage and
medication adherence, using either bivariate comparisons
or multiple regression.en formulary decision support and preferred medication










re: date dispensed, PCP prescribing volume with this insurer, patients’ average
zip code data).
lass, non-users, and claims from the time period prior to
models where we: (1) excluded pediatricians completely, (2) controlled for
) restricted to IS only.
Table 4 Linear mixed effects regression model evaluating the relationship between monthly copayment and
medication adherence (n = 12389)*
Patient or Claim Characteristic† Adherence, expressed as absolute percent changein proportion of days covered
P value
4 ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃCopayment in dollars
p
−8% <0.0001
Medication class – inhaled steroid −49% <0.0001
Zip code-based estimates of patients’ annual income‡
$45 k – $75 k 6% <0.0001
> $75 k 8% <0.0001
Medication dosing frequency greater than once daily −4% <0.0001
*Variables without association, and therefore not used as predictors in this model, are: patient age, gender, history of depression (as evidenced by prior use of
antidepressants), and patient race (as estimated from zip code data).
†The referent categories were as follows: angiotensin receptor blocker medication class, annual income < $45 k annually, and medication dosing less than or equal
to once daily.
‡Estimated based on zip code data. 336 claims were excluded from this analysis due to missing zip code data.
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and copayment:adherence associations with our FDS:tier
model to project the effect of FDS on adherence in a
manner robust to the tier:copayment and copayment:ad-
herence relationships of our studied setting. We thus ap-
plied our estimate of the effect of FDS on tier to the
aforementioned survey data [21] regarding copayment
differences and to a metanalysis of the copayment:
adherence relationship [20]. Using these estimates, we
projected that a patient of a PCP who frequently used e-
prescribing with both interruptive and non-interruptive
FDS could expect to realize cost savings that would
translate to an increase in PDC of 3.6%.
We calculated this number using the expected cost
method explained above, with the previously cited copay-
ments of $29 and $52. Using the 15% increase in preferred
tier prescribing, this yielded an expected copayment de-
crease of $3.49 associated with high usage of FDS. Using
the midrange value of the Goldman et al. [20] estimate of
copayment:adherence associations (a 4% decrease in out
of pocket spending associated with a 10% increase in cost
sharing), and assuming an initial PDC of 60%, we deter-
mined that high usage of FDS could be expected to in-
crease PDC by 3.6%.
Discussion
We found significant associations between high usage of
interruptive FDS and medication tier, tier and copayment,
and copayment and adherence within a single population
of physicians and patients. However, predominantly be-
cause of modest copayment differences between tiers,
there was no significant direct relationship between FDS
and adherence. We begin by comparing each of the initial
three estimates with prior findings.
Because no prior studies concentrated on the effect of
FDS in medication classes without generic alternatives, it
was difficult to directly compare our estimate of the asso-
ciation of FDS with medication tier to those found inthese studies [6,8,22]. Given that there are other methods
of encouraging generic substitution that are now widely
used, we would hold that our study is a much more im-
portant test of the ability of FDS to reduce patients’ drug
costs. Indeed, generic substitution has been successfully
encouraged with broadly targeted educational campaigns
and incentives [23]. In contrast, encouraging the use of
preferred tier medications requires current and patient-
specific formulary data not easily accessed without FDS.
To be sure, although we detected a relationship
between high usage of FDS and medication tier, this
association became non-significant when all FDS users
were considered. A separate study of the effect of e-
prescribing on generic prescribing also reported low
usage rates (20%, versus 23% in our findings), and ad-
justed for these low rates to show the effect of FDS [22].
Greater e-prescribing usage will be needed for FDS to
make an overall impact on medication tier or adherence.
We did find that high usage of e-prescribing with
interruptive and non-interruptive FDS was associated
with nearly 2-fold increased odds for prescribing pre-
ferred tier medications. Such an effect on preferred tier
selection has not been demonstrated before. In today’s
environment of increasing FDS usage, this finding
should encourage pharmacy benefit management com-
panies to apply increased tier price differentials and
thereby enhance their power to negotiate lower pharma-
ceutical prices, with greater confidence that prescribers
will select preferred medications. In turn, as tier price
differentials increase, observers will be better able to as-
sess whether, and to what extent, FDS may be used to
increase adherence. One caveat to implementing FDS in
today’s clinical environments, which may be already
overflowing with sundry forms of clinical decision sup-
port, is that clinicians may be more prone to alert fa-
tigue [24] than the studied PCPs. Indeed, these PCPs
may have adopted standalone e-prescribing partially be-
cause they lacked EHRs.
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interruptive FDS, the non-interruptive FDS alone showed
no improvement in preferred brand prescribing. We attri-
bute this in part to the somewhat cryptic symbols shown
in Figure 2, and recommend clear, intuitive interfaces [25].
The claims we studied showed a very weak tier:copay-
ment association. Indeed, we estimated that preferred
brand ARBs and ISs cost patients only $1.21 and $1.56
less per month than non-preferred brands, respectively.
In contrast, the aforementioned survey data showed
average preferred brand copayments of $29 and non-
preferred brand copayments of $52 in 2013 (even in
2005, during the study time period, this survey showed
copayments of $23 and $40, respectively), versus mean
monthly copayments of $22.95 and $26.61 for these tiers
in our data set [21]. Although this survey data did not
specify the days of medication supplied, the copayment
difference between tiers was more than ten times
greater. The weaker association between tier and copay-
ment we found was likely at least partially because the
actual claims data we used from various pharmaceutical
benefit plans in our dataset differed from the preferred/
non-preferred data points gathered in the survey (vari-
ous examples of plans leading to situations where the
‘preferred’ brand might not have had a lower copayment
are given in the Pharmaceutical Benefit Plans section
above). Despite these differences in the types of data ob-
tained, the much weaker tier:copayment association we
measured shows that the drug benefit plans we studied
use less cost sharing than most US plans.
This weak tier:copayment association likely limited the
effect of the FDS intervention on adherence in two ways.
First, physicians would be more likely to disregard FDS
once they learned that the copayment difference between
tiers was minimal. Second, the limited ability of these rec-
ommendations to substantially reduce copayments would
have tempered their effect on cost-related nonadherence.
For these reasons, we believe this ‘weak link’ in the hy-
pothesized overarching relationship between FDS and ad-
herence to be the main explanation for an undetected
significant relationship between these two variables.
We also compared our model of the effect of medication
copayment on adherence with prior findings. Goldman
et al. systematically reviewed prior literature and found
each 10% increase in cost sharing was associated with a
2% to 6% decrease in out of pocket spending, which
should usually correlate with adherence, at least as mea-
sured by claims [20]. We tested our model with several
average monthly copayments ranging from $5 to $25 to
determine that a 10% increase in cost was associated with
a 0.3% to 0.4% decrease in PDC. Thus, our measured ef-
fect size was approximately one order of magnitude
smaller than prior estimates. We found no obvious cause
for this discrepancy.Given that our tier:copayment and copayment:adher-
ence associations were much weaker than prior findings
and may have been unique to the studied setting, we
also combined prior estimates of these relationships with
our FDS:tier model to predict the most likely effect of
FDS on adherence. We applied our estimate of the effect
of FDS on tier to the aforementioned survey data re-
garding copayment differences and to the Goldman
et al. estimates of the copayment:adherence relationship.
Using these estimates, we projected that a patient with a
PCP who used e-prescribing with both interruptive and
non-interruptive FDS more than 30% of the time could
expect to realize cost savings that would translate to an
increase in PDC of 3.6 percent.
Our results suggest that FDS can only be expected to
substantially impact adherence among patient popula-
tions whose PCPs are predominantly high users of FDS.
Indeed, the observed changes in adherence were sub-
stantially limited by low physician usage of FDS. “High”
user PCPs used FDS as infrequently as 30% of the time,
and had mean usage rates of 61% [12]. However, since
the time of our study, multiple government incentives
[26,27] have increased nationwide e-prescribing usage
rates to 44% of all prescriptions dispensed [28]. Thus, a
substantial proportion of today’s highest FDS users are
likely realizing PDC gains above 3.6%. Today’s higher
copayment differentials would also increase the effect of
FDS on adherence.
Beyond confirming the three hypothesized relationships,
we found several other results to be consistent with prior
findings. For example, higher dosing frequency and lower
patient income were associated with decreased adherence.
Our estimated adherence rates for ARBs were vastly
greater than those for IS medications, which is consistent
with prior reports [9,13-16]. At least some of this differ-
ence may be attributed to seasonal prescribing of IS for al-
lergic asthma. We have thus also considered that our
measured usage of preferred tier IS medications could
underestimate true use of preferred tier IS among new
users, at least to the extent that seasonal users requesting
previously successful, but non-preferred tier IS medica-
tions could have been erroneously identified as new users
in our analysis, because we only looked back six months
to identify new users. Nonetheless, we found much lower
rates of preferred tier use IS users than among ARB users.
This may have been due to greater differences (perceived
or real) among ARB versus IS medications, or it could also
have stemmed from the proportion of preferred tier medi-
cations available (two preferred tier ARB out of seven total
ARB, versus two preferred IS out of only five total IS). We
found similar tier:copayment relationships in each class,
suggesting that copayment was not a major factor explain-
ing differential prescribing of preferred tier medications
across classes.
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tially found an unexpectedly strong association between
pediatric PCPs and use of preferred brand medications
(OR 11.2, p < .0001). Although including this predictor did
not alter the OR of 1.9 for e-prescribing with interruptive
and non-interruptive FDS among high users, we decided
not to include this predictor in the FDS:tier model de-
scribed in Table 3. It was excluded because there were
only a small number of claims from patients with pediatric
PCPs, and because this small number of claims substan-
tially affected the overall FDS:tier model such that the pre-
dicted probability of preferred tier medications differed
substantially from our raw data.
Limitations
One limitation of our analysis was that we could not deter-
mine whether individual claims had been electronically pre-
scribed. Usage rates were instead estimated at the physician
level from a 2006 usage evaluation period, and our prior
work showed that usage was relatively stable [12]. Lacking
a prescription-level linkage probably biases our estimates
toward the null hypothesis, but given the mean usage level
of 61% in the high-use group it is also reasonable to view
our estimates as more similar to the real-world effects one
might find from an effective e-prescribing program. We
also lacked data on the potential use of e-prescribing by
control physicians (obtained outside of the studied program
that offered e-prescribing with FDS to all of the included
physicians), but survey data even more recent than these
claims showed only 4% of US physicians had adopted “fully
functional” electronic medical records that included e-
prescribing capabilities [29]. Only a subset of this 4% would
have had FDS, and a smaller subset would have been using
FDS frequently. Thus, we believe that unmeasured usage of
FDS did not substantially bias our results. If there were bias,
it would be towards the null hypothesis.
Even though we examined data from just one standa-
lone e-prescribing product implemented in 2005, we ex-
pect our results and conclusions to generalize, and to be
included in updates to a recent issue brief that found no
evidence on this topic [11]. E-prescribing products used
today have more features, improved usability, and are
more likely to be part of an integrated EHR. Although
these conveniences are surely helpful, they use the same
formulary and benefits standard to transmit the same in-
formation via the same interruptive and non-interruptive
alerting mechanisms we studied. To be sure, the early
adopting physicians who began using e-prescribing in
2005 could differ from physicians who have not yet
adopted e-prescribing today, and we cannot exclude the
possibility that these differences could lead to a different
result from the use of FDS.
We focused on the benefit of FDS in medication clas-
ses without generic options. Although many commonlyused medications, including ARB and IS, now have gen-
eric alternatives, a variety of other mechanisms are being
used successfully to increase generic substitution. Further-
more, new drug classes are continuously emerging, with
generics naturally lagging, and formulary tier will continue
to be used as a tool for competitive contracting.
To best address these issues, we considered many repre-
sentative candidate classes. The ARB and IS classes were
the best choices in terms of containing clinically similar,
multi-tiered medications without generic alternatives dur-
ing the three year study time period. We acknowledge that
there are subtle clinical differences between the medica-
tions in these classes. Nonetheless, these differences need
not restrict the choice of initial medication, and our differ-
ence in differences design means that any PCP percep-
tions regarding superiority would have been very unlikely
to affect our results. Finally, although we believe that the
characteristics of these medication classes are similar to
many other classes used for chronic diseases, it would be
important to study whether our findings generalize to
acute care, where e-prescribing may be less prevalent.
Another limitation is that we used a difference in dif-
ferences methodology to analyze the results of a real
world initiative, rather than a planned experiment. Be-
cause PCPs themselves decided whether they would
adopt and use FDS, there may have been selection bias.
For example, PCPs more attuned to copayments may
have been more likely to adopt and use FDS. However,
high users’ unadjusted preferred tier usage of 57% before
e-prescribing was the lowest of any PCP group in any
time period, suggesting that these users were not predis-
posed to choosing preferred brands. Nonetheless, if the
high user group possessed some other characteristic (e.g.
more educated patient populations, who might both be
healthier and have less aversion to lower-tiered medica-
tions) that made them more amenable to low tiered pre-
scribing when exposed to the intervention, then FDS
might not work the same for other physicians lacking
this characteristic. This limitation is common to nearly
all observational studies.
As with most any study, more data could have im-
proved our analysis. For the time period with e-
prescribing and interruptive FDS, upon which we relied
for our most important results, we had over nine
months of data as a result of a one-time data extract for
a larger project [30]. Nonetheless, more claims would be
useful to observe whether, and to what extent, the ob-
served increase in preferred tier prescribing persisted
over time.
Our transformation of the copayment variable has the ad-
vantages of improving model fit and satisfying the assump-
tions behind the statistical model. However, it can hamper
interpretability, and partially for this reason we have pro-
vided several examples of how copayment differences are
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we studied a patient population with a heterogeneous mix
of pharmaceutical benefit plans, which provides good
generalizability because it resembles real-world conditions.
As in most cases, this generalizability comes at a cost of re-
duced internal validity. To the extent that studied plans de-
viated from a tiered benefit plan with set copayments, our
results would have been biased towards the null hypoth-
eses. Internal validity might be further optimized, though
external validity adversely impacted, by studying PCPs
whose patients had identical pharmaceutical benefit plans.
Conclusion
In evaluating the relationship between FDS and adherence,
we have provided the most direct evidence to date that
FDS can be useful in helping physicians to choose preferred
brands, rather than just contributing to generic substitu-
tion. In the studied population, interruptive FDS shifted
prescribing toward preferred tier medications, but these
medications were only minimally less expensive for pa-
tients. Thus, FDS did not significantly increase adherence.
To impact cost-related non-adherence, FDS will likely need
to be paired with complementary drug benefit design.
Combining our estimate of the FDS effect on tier with
more generalized prior findings regarding tier:copayment
and copayment:adherence relationships demonstrates that
FDS holds promise for policymakers and health system
leaders to increase adherence.
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